Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Core Insights - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for cancer, specifically targeting clinically proven kinase targets [3]. Company Participation - The CEO James Porter, Ph.D., and CFO Alexandra Balcom will participate in a fireside chat during the UBS 2025 Virtual Oncology Day on October 1, 2025, at 3:30 p.m. ET [1]. Webcast Information - A live webcast of the event will be available on the company's website and archived for 30 days post-presentation [2]. Company Overview - Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3]. - The company leverages expertise in chemistry and structure-based drug design to develop innovative small molecules aimed at overcoming resistance, minimizing adverse events, and addressing brain metastases [3].